Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equa

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndr

FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest tre

Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activati

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfil

Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved fo

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the d

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the d

The U.S ​Food ‌and Drug ​Administration ​said on Thursday ⁠it ​has ​approved Ultragenyx's gene ​ther

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ne

Analysts downgraded UiPath, Cal-Maine with several price-target cuts.

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight

JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight

Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and

Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regu

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goa

Citigroup analyst Yigal Nochomovitz maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy

Martin Shkreli, known as Pharma Bro, said Ultragenyx Pharmaceutical (NASDAQ:RARE) is undervalued and

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial f

U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lo

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Ove

U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and R

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a B

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is tumbling on Thursday after reporting late-stag

Ultragenyx reports Phase 3 Aspire study of apazunersen failed to meet primary endpoints, prompting p

Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.

Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, Crowd

Evercore ISI Group analyst Liisa Bayko downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Ou

Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market se

Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, o

U.S. futures rose, but NetApp fell 8.2% after earnings. Ultragenyx plunged 45% on a failed trial; HP

Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains s

Baird analyst Joel Beatty downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Outperform to N

AVGO: -5% | AVGO stock has given up its prior loss. Broadcom shares were trading lower after the com

Shares of Ultragenyx Pharmaceutical plunged more than 40% in premarket on Thursday after its neurode

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ultragenyx Pharmaceutical (NASDAQ:RA

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a

Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers an

Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-mar

Ultragenyx Pharmaceutical said on ‌Wednesday its experimental drug for a rare genetic neurodevelopme

Phase 3 Aspire did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive ra